Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

• DOI: 10.1136/rmdopen-2020-001525
• Publication Date: 2021-02-07T04:26:05Z
• Authors: Ulf Sundin; Nina Paulshus Sun...; Anna-Birgitte Aga; Joseph Sexton; Lena Bugge Nordberg; Hilde Berner Hammer; Desirée van der H...; Tore K Kvien; Espen A Haavardsholm; Siri Lillegraven
• Keywords: Tenosynovitis; Univariate analysis

Objectives To investigate if inflammation detected by MRI or ultrasound at rheumatoid arthritis (RA) onset is predictive of erosive progression poor response to methotrexate monotherapy, and subclinical in remission future treatment escalation progression. Methods In a 2-year study, 218 patients with disease-modifying antirheumatic drug-naïve early RA were treated tight-control treat-to-target strategy corresponding current recommendations. performed regular intervals. Baseline imaging-based measures analysed as predictors for failure using univariate multivariate regression adjusted clinical, laboratory radiographic measures. after 1 year, imaging during the second year. The added value prediction models was assessed receiver operating characteristic analyses. Results associated No measure failure. Imaging present majority clinical remission. Tenosynovitis escalation, synovitis tenosynovitis MRI/radiographic information did not improve any outcomes. Conclusions Imaging-detected inflammation, both diagnosis remission, elements disease development. However, lack significant effect on indicates limited systematic management RA.